• Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis

  NCT07093203

  RecruitingObservationalUpdated Apr 1, 2026
• Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

  NCT03667690

  CompletedInterventionalPhase 3Updated Jan 6, 2023
• Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

  NCT04368559

  CompletedInterventionalPhase 3Updated Apr 13, 2026
• Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

  NCT05534529

  TerminatedInterventionalPhase 1Updated Apr 6, 2025
• Rezafungin Prophylaxis in Liver Transplant

  NCT06774144

  Enrolling by invitationInterventionalPhase 3Updated Oct 20, 2025
• Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

  NCT00496197

  CompletedInterventionalPhase 4Updated Oct 3, 2011

ClinicalTrials.gov ID

NCT06985758

Lead Sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

20Estimated

Last Update Posted

Jun 22, 2025Actual

Start Date

Sep 2025Estimated

Primary Completion Date

Nov 2025Estimated

Completion Date

Jan 2026Estimated

Official Title

Phase IV, Open-label, Single Arm, Multicenter Trial to Evaluate Pharmacokinetic Parameters of Peritoneal Diffusion and Peritoneal Diffusion Activity.

Brief Summary

Intra-abdominal candidiasis is the most frequent candidiasis infection after candidemia. The studies that have positioned echinocandins as the first therapeutic option in candidiasis have been carried out mainly in patients with candidemia. Peritoneal concentrations of caspofungin, micafungin and anidulafungin are clearly above the MICs of most Candida spp but are below the threshold for selection of resistant mutants, which has been argued by some researchers as a risk for the control of intra-abdominal infections with poor control of the focus and selection of resistant mutants, observed in Candida spp isolates at the peritoneal level in relation to isolates at the blood culture level.

Rezafungin, with its special pharmacokinetics, achieves higher tissue concentrations, including hepato-splenic and other abdominal organs, than the other echinocandins. Experimental studies have confirmed that the concentration of rezafungin at the level of the inflammatory focus in abdominal infections is higher than in the surrounding healthy tissue and higher than those achieved by micafungin. Finally, the biofilm activity of rezafungin is very high, clearly superior to fluconazole and possibly higher than that of other echinocandins.

Detailed Description

Intra-abdominal candidiasis is the most common candidal infection after candididaemia. Studies that have positioned echinocandins as the first therapeutic option in candidiasis have been conducted primarily in patients with candidaemia. Peritoneal concentrations of caspofungin, micafungin and anidulafungin are clearly above the MICs of most Candida spp but are below the threshold for selection of resistant mutants, which has been argued by some researchers as a risk for the control of intra-abdominal infections with poor control of the focus and selection of resistant mutants, observed in Candida spp isolates at the peritoneal level relative to isolates at the blood culture level.

Rezafungin has the characteristic of having a modified chemical structure that gives it greater stability and a prolonged half-life, allowing the drug to be administered less frequently on a weekly rather than daily basis. This results in greater clearance of candidemia and greater penetration and persistence in tissues compared to other echinocandins, and improves patient adherence to treatment.

The efficacy of Rezafungin has already been evaluated in clinical trials, and has been shown to be equal or superior to that of other echinocandins, and because it has a low incidence of cross-resistance with other antifungals, it is an appropriate choice for resistant fungal infections.

• Candidal Peritonitis

• Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients with suspicion, confirmed or not, of candidiasis peritonitis or intra-abdominal infection by Candida spp. who, after having received information about the design, the purpose of the study, the possible risks that may arise from it and that they can refuse to collaborate at any time, give written consent to participate in the study.
• Be over 18 years of age
• Understand the purpose of the study and be available to perform the visits and procedures established in the protocol
• In women: negative urine pregnancy test performed in the 7 days prior to the start of study treatment in women of childbearing age and if < 2 years have passed after menopause
• Patients with signs of peritonitis or intra-abdominal infection showing refractoriness after at least 48 hours of empirical or specific antibiotherapy and in whom candidiasis infection is suspected.
• Patients with abdominal or peritoneal drainage with permeable debit that allows obtaining peritoneal samples through it.

Exclusion Criteria:

• Patients in whom there is any contraindication for use according to the established in the technical data sheet or known hypersensitivity to rezafungin or who, according to the investigator's criteria, it is not advisable to participate.
• Patients who do not present suspicion of intra-abdominal candidiasis infection or who are receiving antifungal treatment for another reason.
• Patients receiving another antifungal drug during rezafungin administration.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER

nurial.perez@salud.madrid.org+34917277273